171178-43-1

Basic information

• Product Name: 5-AMINO-2-FLUORO-ISONICOTINIC ACID
• Synonyms: 5-AMINO-2-FLUOROPYRIDINE-4-CARBOXYLIC ACID;5-AMINO-2-FLUORO-ISONICOTINIC ACID;5-Amino-2-fluoro-4-pyridinecarboxylic acid;4-Pyridinecarboxylicacid,5-amino-2-fluoro-(9CI);5-AMINO-2-FLUOROPYRIDINE-4-CARBOXYLIC AC;5-Amino-2-fluoropyridine-4-carboxylic acid, 5-Amino-4-carboxy-2-fluoropyridine;5-AMino-2-fluoro-isonicotinic acid Methyl ester;4-Pyridinecarboxylicacid, 5-amino-2-fluoro-
• CAS NO: 171178-43-1
• Molecular Formula: C6H5FN2O2
• Molecular Weight: 156.11
• Product Categories: CARBOXYLICACID;HALIDE;pharmacetical;Pyridine;Pyridines
• Mol File: 171178-43-1.mol

Chemical Properties

• Boiling Point: 514.394 °C at 760 mmHg
• Flash Point: 264.896 °C
• Appearance: /
• Density: 1.535±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.77±0.10(Predicted)
• CAS DataBase Reference: 5-AMINO-2-FLUORO-ISONICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-2-FLUORO-ISONICOTINIC ACID(171178-43-1)
• EPA Substance Registry System: 5-AMINO-2-FLUORO-ISONICOTINIC ACID(171178-43-1)

Safety Data

• Hazardous Substances Data: 171178-43-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-AMINO-2-FLUORO-ISONICOTINIC ACID is used as a key intermediate in the synthesis of pharmaceuticals for its potential biological activity. Its unique structure allows for the development of new drugs and bioactive molecules with therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 5-AMINO-2-FLUORO-ISONICOTINIC ACID serves as a building block in the creation of compounds with pesticidal or herbicidal properties, contributing to the development of effective and environmentally friendly solutions for crop protection.
Used in Chemical Research:
5-AMINO-2-FLUORO-ISONICOTINIC ACID is utilized as a versatile tool in chemical research for creating novel compounds with potential therapeutic applications. Its unique properties make it an essential component in the exploration of new chemical entities and their potential uses in various fields.

InChI:InChI=1/C6H5FN2O2/c7-5-1-3(6(10)11)4(8)2-9-5/h1-2H,8H2,(H,10,11)

Upstream product

• 171178-42-0 5-[N-(tert-Butoxycarbonyl)-amino]-2-fluoropyridine-4-carboxylic acid 
• 1827-27-6 2-fluoro-5-aminopyridine 
• 171178-41-9 (6-fluoro-pyridin-3-yl)-carbamic acid, tert-butyl ester 
• 456-24-6 2-Fluoro-5-nitropyridine 
• 4548-45-2 2-chloro-5-nitropyridine 

Downstream Products

• 171178-44-2 6-fluoro-4-oxo-3H-pyrido[3,4-d]pyrimidine 
• 175357-98-9 4-chloro-6-fluoro-pyrido[3,4-d]pyrimidine 
• 2135696-72-7 (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide 

Relevant articles and documents

USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS

Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti- HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti -HER2/HER3 antibodies.

HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

Syntheses of [14C] and [2H4]PD0205520, an inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor

5-(4-Methyl-piperazin-1-yl)-pent-2-ynoic acid [4-(3-chloro-4-fluoro- phenylamino)-pyrido[3,4-d]pyrimidin-6-yl]-amide, PD0205520, was under investigation as a potential inhibitor of the tyrosine kinase (TK) activity of the epidermal growth factor receptor (EGFR) for cancer treatment. Both radio- and stable-isotope-labeled compounds were required for drug absorption, distribution, metabolism and excretion (ADME) and quantitative mass spectrometry bio-analytical studies. PD0205520 14C-labeled in the pyrimidine ring system was prepared in seven steps in an overall radiochemical yield of 26% from [14C]thiourea. PD0205520 2H-labeled in the piperazine ring was synthesized in four steps in a 32% overall yield. Copyright

Process for preparing 4,6-disubstituted pyrido[3,4-d]pyrimidines

An improved process for the preparation of 4,6-disubstituted pyrido[3,4-d]pyrimidines is described where 5-amino-2-fluoropyridine is converted in seven operations to the desired products, as well as other valuable intermediates used in the process.

Synthesis of 6-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones via directed lithiation of 2-substituted 5-aminopyridine derivatives

Directed lithiation of Boc or pivaloyl derivatives of 2-substituted 5-aminopyridines with BuLi-TMEDA in diethyl ether at -10°C gave 4-lithio derivatives which were quenched with CO2 to give the analogous C-4 carboxylic acids. Hydrolysis of the protecting groups with either TFA or aqueous KOH gave 2-substituted 5-aminopyridine-4-carboxylic acids which were converted to 6-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones by reaction with formamide or, more optimally, formamidine acetate. Boc protected aminopyridines provided the best overall results, with synthesis of these derivatives best achieved by direct reaction of the aminopyridine with di-tert-butyl dicarbonate in the absence of added base.